Pharmacotherapy for overweight/obesity in ethnic minorities and white caucasians : a systematic review and meta-analysis
Osei-Assibey, G., Adi, Y., Kyrou, Ioannis, Kumar, Sudhesh and Matyka, K.. (2011) Pharmacotherapy for overweight/obesity in ethnic minorities and white caucasians : a systematic review and meta-analysis. Diabetes, Obesity and Metabolism, Volume 13 (Number 5). pp. 385-393. ISSN 1462-8902Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1463-1326.2010.01346.x
Ethnic minorities in the West exhibit a higher prevalence of obesity and also under-achieve in weight management compared to White Caucasians. A systematic review of randomized controlled trials (RCTs) in adults (mean age >= 18 years, duration >= 6 months and published in the English language) was undertaken to evaluate the effectiveness of antiobesity drugs in ethnic minorities and White Caucasians. Data sources between 1990 and 2010 were searched including MEDLINE, EMBASE, Cochrane Controlled Trials Register, CINAHL and references cited in the included studies of other reviews. Eighteen RCTs that met the inclusion criteria were included in this review (6 sibutramine and 12 orlistat). A random effects model was used for meta-analysis. An indirect comparison of weight loss in sibutramine-treated patients in ethnic minorities was significantly lower than in White Caucasians: -2.7 kg (95% CI: -3.1 to -2.3) versus -4.4 kg (95% CI: -5.0 to -3.8), respectively. For orlistat, weight loss was similar in the two groups: -2.3 kg (95% CI: -2.6 to -2.0) in ethnic minorities and -2.8 kg (95% CI: -5.1 to -0.5) in White Caucasian participants. Overall, there were few studies of weight loss pharmacotherapy for comparison of this review and it was not possible to analyse data based on ethnic groupings. More ethnically tailored studies are needed to assess the most effective weight loss strategies in these most metabolically vulnerable groups.
|Item Type:||Journal Article|
|Subjects:||R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI)
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Appetite depressants, Chemotherapy, Weight loss preparations, Weight loss, Systematic reviews (Medical research), Meta-analysis|
|Journal or Publication Title:||Diabetes, Obesity and Metabolism|
|Page Range:||pp. 385-393|
|Access rights to Published version:||Restricted or Subscription Access|
|Funder:||Produits Roche S.A.|
|References:||1. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health 2004; 58: 441–445. 2. Health Survey for England. The Health of Minority Ethnic Groups. NHS Health and Social Care Information Centre, Public Health Statistics 2004. Available from URL: http://www.ic.nhs.uk. Accessed 27 June 2007. 3. Ogden CL, Carrol MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006; 295: 1549–1555. 4. Parikh M, Lo H, Chang C, Collings D, Fielding G, Ren C. Comparison of outcomes after laparoscopic adjustable gastric banding in African- Americans and whites. Surg Obes Relat Dis 2006; 2: 607–610. 5. Kumanyika SK, Obarzanek E, Stevens VJ, Hebert PR, Whelton PK. Weightloss experience of black and white participants in NHLBI-sponsored clinical trials. Am J Clin Nutr 1991; 53: 1631S–1638S. 6. Buffington CK, Marema RT. Ethnic differences in obesity and surgical weight loss between African-American and Caucasian females. Obes Surg 2006; 16: 159–165. 7. Hong K, Li Z, Wang H-J, Elashoff R, Heber D. Analysis of weight loss outcomes using VLCD in black and white overweight and obese women with and without metabolic syndrome. Int J Obes 2005; 29: 436–442. 8. Wing RR, Anglin K. Effectiveness of a behavioural weight control program for blacks and whites with NIDDM. Diabetes Care 1996; 19: 409–413. 9. McMahon FG, Fujioka K, Singh BN et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. Arch Intern Med 2000; 160: 2185–2191. 10. Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as ‘‘syndromes of impaired genetic homeostasis’’: the ‘‘thrifty genotype’’ hypothesis enters the 21st century. Perspect Biol Med 1998; 42: 44–74. 11. Bower JF, Vadlamudi S, Barakat HA. Ethnic differences in in-vitro glyceride synthesis in subcutaneous and omental adipose tissue. Am J Physiol Endocrinol Metab 2002; 283: E988–E993. 12. Bower J, Deshaies Y, Pfeifer M, Tanenberg RJ, Barakat HA. Ethnic differences in post-prandial triglyceride response to a fatty meal and lipoprotein lipase in lean and obese African American and Caucasian women. Metabolism 2002; 51: 211–217. 13. Privette JD, Hickner RC, Macdonald KG, Pories WJ, Barakat HA. Fatty acid oxidation by skeletal muscle homogenates from morbidly obese black and white American women. Metabolism 2003; 52: 735–738. 14. Nicklas BJ, Berman DM, Davis DC, Dobrovolny CL, Dennis KE. Racial differences in metabolic predictors of obesity among postmenopausal women. Obes Res 1999; 7: 463–468. 15. Desmond SM, Price JH, Hallinan C, Smith D. Black and white adolescents’ perceptions of their weight. J Sch Health 1989; 59: 353–358. 16. Rand CS, Kuldau JM. The epidemiology of obesity and self-defined weight problem in the general population. Gender, race, age, and social class. Int J Eat Disord 1990; 9: 329–343. 17. Kahn HS, Williamson DF, Stevens JA. Race and weight change in US women: the roles of socioeconomic and marital status. Am J Public Health 1991; 81: 319–323. 18. Kumanyika S, Wilson JF, Guilford-Davenport M. Weight related attitudes and behaviors of black women. J Am Diet Assoc 1993; 93: 416–422. 19. National Institute of Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. Full guideline (2006), reference CG43. Available from URL: http://www.nice.org.uk/guidance/index. Assessed 18 December 2007. 20. National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6(Suppl. 2): 51S–209S. 21. Bray GA. Medications for obesity: mechanisms and applications. Clin Chest Med 2009; 30: 525–538. 22. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003; 27: 1437–1446. 23. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194–1199. doi:10:1136/bmj.39385.413113.25. 24. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes 2005; 29: 1153–1167. 25. Glenny AM, O’Meara S, Melville A, Sheldon TA, Wilson C. The treatment and prevention of obesity: a systematic review of the literature. Int J Obes 1997; 21: 715–737. 26. O’Meara S, Riemsma R, Shirran L,Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for themanagement of obesity. Obes Rev 2004; 5: 51–68. 27. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii–iv, 1–182. 28. PRISMA Statement. Available from URL: http://www.prisma-statement. org. Accessed 27 August 2010. 29. Verhagen AP, de Vet HC, de Bie RA et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235–1241. 30. Juni P, Smith GD, Altman DG. Assessing the quality of randomised controlled trials. In: Egger M, Smith GD, Altman DG eds. Systematic Reviews in Health Care, 2nd edn. London: BMJ Publishing Group, 2001; 87–108. 31. STATSDIRECT Statistical Software version 2.6.6, StatsDirect Ltd, Cheshire, UK. Available from URL: http//www.statsdirect.com. Accessed 2008/2009. 32. Egger M, Davey GS, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629–634. 33. Ades AE, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005; 25: 646–654. 34. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K., Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5–11. 35. Dujovne CA, Zavoral JH, Rowe E, Mendel CM., Sibutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001; 142: 489–497. 36. Fujioka K, Seaton TB, Rowe E et al. Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175–187. 37. Porter JA, Raebel MA, Conner DA et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) Study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004; 10: 369–376. 38. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111–2120. 39. Poston WSC, Haddock CK, Pinkston MM et al. Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J Intern Med 2006; 260: 388–398. 40. Poston WSC, Reeves RS, Haddock CK et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes 2003; 27: 1486–1493. 41. Garcia JM, Iyer D, Poston WSC et al. Rise of plasma ghrelin with weight loss is not sustained during weight maintenance. Obesity 2006; 14: 1716–1722. 42. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat: a randomized controlled trial. JAMA 1999; 281: 235–242. 43. Dixon AN, Valsamakis G, Hanif MW et al. Effect of the orlistat on serum endotoxin lipo-polysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int J Clin Pract 2008; 62: 1124–1129. 44. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR., Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160–167. 45. Heymsfield SB, Segal KR, Hauptman J et al. Effects of weight loss with Orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321–1326. 46. Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69: 1108–1116. 47. Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a randomized double-blind study. Diabetes Care 1998; 21: 1299–1294. 48. Kelley DE, Bray GE, Pi-Sunyer FX et al. Clinical efficacy of Orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002; 25: 1033–1041. 49. Miles JM, Letter L, Hollander P et al. Effect of Orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123–1128. 50. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized prospective trial. Hepatology 2009; 49: 80–86. 51. Hussain-Gambles M. Ethnic minority under-representation in clinical trials. J Health Organ Manag 2003; 17: 138–143. 52. Kumanyika SK, Morssink CB. Cultural appropriateness of weight management programs. In: Dalton S ed. Overweight and Weight Management. Gaithersburg, MD: Aspen, 1997; 69–106. 53. European Medicines Agency (EMA) updates on ongoing safety review of sibutramine: weight lossmedicines assessed over cardiovascular concerns. Available from URL: http://www.ema.europa.eu/pdfs/general/direct/ pr/81787609.pdf. Accessed 2010. 54. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration, 2009. Available from URL: http://www.cochrane-handbook.org. Accessed September 2009.|
Actions (login required)